Get the Stockscreener App
0.58
0.85%
-0.005
After Hours:
.58
Oragenics Inc stock is traded at $0.58, with a volume of 34,120.
It is down -0.85% in the last 24 hours and down -2.36% over the past month.
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
See More
Previous Close:
$0.585
Open:
$0.594
24h Volume:
34,120
Relative Volume:
0.62
Market Cap:
$2.62M
Revenue:
$7,500
Net Income/Loss:
$-9.84M
P/E Ratio:
-0.1013
EPS:
-5.7263
Net Cash Flow:
$-9.25M
1W Performance:
-1.69%
1M Performance:
-2.36%
6M Performance:
-33.33%
1Y Performance:
-62.09%
1-Day Range:
$0.5694
$0.6092
1-Week Range:
$0.55
$0.61
52-Week Range:
$0.5038
$1.57
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.58 | 2.62M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oragenics Inc Stock (OGEN) Latest News
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oragenics Inc (OGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Spread - newsline.com
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Volatility Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
Oragenics Inc. (OGEN) Gains Ground: Potential Breakout Above $0.65 in Sight?Swing Trade Setups - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
ORAGENICS INC (OGEN) Stock Chart - ChartMill
OGEN Q2 2023 Earnings: Narrower-than-expected loss as EPS beats estimates by over 50%Annual Earnings Summary - dars.gov.et
Oragenics Inc. (OGEN) Inches Higher as Stock Tests Key Resistance Near $0.64SuperTrend Flip - newsline.com
Oragenics Inc. (OGEN) Slips Amid Low Volume, Hovers Near Key SupportIceberg Order - newsline.com
Oragenics Inc. (OGEN) Edges Higher as Biotech Volatility PersistsIceberg Order - The Legal Advocate
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor SentimentOpen Signal Network - Newser
OGEN | Oragenics Inc. Executive Compensation - Quiver Quantitative
Oragenics Q2 2023 Earnings: Narrowing Loss Surprises, No Revenue YetFull Year Guidance - Newser
Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - marketscreener.com
Oragenics (OGEN) Rallies +4.50% as Bulls Target $0.63 2026-05-20Community Buy Signals - Newser
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment - MEXC
Oragenics Highlights Investor Outreach at Micro-Cap Conference - TipRanks
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - Yahoo Finance
Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device - TradingView
ORAGENICS PROVIDES INVESTOR UPDATE - Sahm
Oragenics (OGEN) Q2 2023 Earnings Surprise: EPS $-1.51, Up SignificantBanking Earnings Report - Newser
Oragenics Advances Phase IIa Trial for Concussion Treatment, Eyes CNS Expansion - citybuzz -
Oragenics advances concussion drug trial, signs device LOI - Investing.com UK
Oragenics advances concussion drug trial, signs device LOI By Investing.com - Investing.com Nigeria
OGEN Technical Analysis | Trend, Signals & Chart Patterns | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
TradingKey - TradingKey
Oragenics (OGEN) continues pipeline investments amid losses; CEO discusses strategic priorities and funding outlook.Crowd Entry Points - Newser
Oragenics: Q1 Earnings Snapshot - 10tv.com
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oragenics | 10-Q: Q1 2026 Earnings Report - Moomoo
Oragenics Signs LOI to License CardioDialysis Technology for Neurodegenerative Diseases - citybuzz -
Oragenics signs letter of intent to license blood purification tech - Investing.com
Oragenics signs letter of intent to license blood purification tech By Investing.com - Investing.com Australia
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - ChartMill
Oragenics Inc Stock (OGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):